CO-ADMINISTRATION OF CICLESONIDE WITH A POTENT INHIBITOR OF THE CYP3A4 SYSTEM (E.G., KETOCONAZOLE, ITRACONAZOLE, RITONAVIR AND NELFINAVIR) SHOULD BE CONSIDERED WITH CAUTION BECAUSE THERE MIGHT BE AN INCREASE IN CICLESONIDE/METABOLITE SERUM LEVELS, WHICH LEADS TO INCREASED RISK OF CLINICAL ADVERSE EFFECTS (E.G., CUSHINGOID SYNDROME).